Daily Ards Research Analysis
Three studies advance ARDS science across therapy, biomarkers, and mechanisms: (1) invimestrocel, a cell-based therapy, was associated with more ventilator-free days and improved survival versus matched historical controls in pneumonia-induced ARDS; (2) circulating GLP-1 correlated with systemic inflammation and 90-day mortality in acute respiratory failure; and (3) Scutellaria barbata extract dampened neutrophil-driven inflammation and mitigated lung injury in a murine ARDS model.
Summary
Three studies advance ARDS science across therapy, biomarkers, and mechanisms: (1) invimestrocel, a cell-based therapy, was associated with more ventilator-free days and improved survival versus matched historical controls in pneumonia-induced ARDS; (2) circulating GLP-1 correlated with systemic inflammation and 90-day mortality in acute respiratory failure; and (3) Scutellaria barbata extract dampened neutrophil-driven inflammation and mitigated lung injury in a murine ARDS model.
Research Themes
- Regenerative cell therapy for ARDS
- Biomarker-driven prognostication in acute respiratory failure
- Neutrophil-targeted anti-inflammatory strategies from ethnopharmacology
Selected Articles
1. Scutellaria barbata ameliorates acute respiratory distress syndrome by inhibiting neutrophil-mediated inflammatory responses.
Using human neutrophils and an LPS-induced murine ARDS model, the authors show that Scutellaria barbata ethanol extract suppresses key neutrophil effector functions and signaling (Akt/p38, Ca2+), reducing lung injury and oxidative stress without cytotoxicity. This supports neutrophil-targeted phytotherapeutics as a mechanistic avenue in ARDS.
Impact: Identifies a mechanistically grounded, neutrophil-targeted anti-inflammatory strategy with in vitro and in vivo validation, opening a novel translational path for ARDS where effective pharmacotherapies remain limited.
Clinical Implications: While preclinical, these data justify exploration of standardized S. barbata derivatives or active constituents as adjunctive therapies to modulate neutrophilic inflammation in ARDS.
Key Findings
- SB-EtOH inhibited respiratory burst, degranulation, and chemotaxis in activated human neutrophils without cytotoxicity.
- SB-EtOH attenuated Akt and p38 phosphorylation and reduced calcium mobilization in neutrophils.
- In an LPS-induced ARDS mouse model, SB-EtOH reduced pulmonary neutrophil infiltration, lung tissue damage, and oxidative stress.
Methodological Strengths
- Integrated human primary cell assays with in vivo murine ARDS model.
- Mechanistic interrogation of signaling pathways (Akt/p38, calcium mobilization).
Limitations
- Complex herbal extract; active constituents and pharmacokinetics not defined.
- Preclinical findings; no human safety or efficacy data.
Future Directions: Isolate and characterize active compounds, define dose–response and PK/PD, and progress to safety/feasibility trials targeting neutrophilic ARDS phenotypes.
ETHNOPHARMACOLOGICAL RELEVANCE: The traditional medicinal herb Scutellaria barbata D. Don (commonly known as Ban Zhi Lian) is renowned for its heat-clearing and detoxifying properties and has been used to treat inflammatory conditions and various cancers. While lung inflammation is an indication for S. barbata, its effects on acute respiratory distress syndrome (ARDS) remain unclear. AIM OF THE STUDY: Dysregulated neutrophilic inflammation plays a critical role in the pathogenesis of ARDS. In this study, we aimed to investigate the novel application of S. barbata in treating neutrophilic inflammation and ARDS. We evaluated the therapeutic potential of the ethanol extract of S. barbata (SB-EtOH) in mitigating neutrophil-driven inflammatory responses. MATERIALS AND METHODS: The chromatographic fingerprint of SB-EtOH was analyzed, and its ethnopharmacological mechanisms were examined for their effects on inflammatory responses in human neutrophils. The therapeutic potential of SB-EtOH was further assessed using a mouse model of lipopolysaccharide (LPS)-induced ARDS. RESULTS: SB-EtOH significantly inhibited respiratory burst, degranulation, and chemotactic responses in activated human neutrophils without cytotoxic effects. Additionally, SB-EtOH attenuated phosphorylation of key inflammatory signaling molecules, Akt and p38, while reducing calcium mobilization in activated human neutrophils. In the LPS-induced ARDS mouse model, SB-EtOH reduced pulmonary neutrophil infiltration, lung tissue damage, and oxidative stress accumulation. CONCLUSION: These findings suggest that S. barbata is a promising therapeutic candidate for ARDS and other neutrophil-predominant inflammatory diseases by mitigating neutrophilic inflammation.
2. Clinical efficacy of invimestrocel for acute respiratory distress syndrome caused by pneumonia: Comparison with historical data using propensity score analysis.
In pneumonia-induced ARDS, invimestrocel recipients had significantly more ventilator-free days and improved survival compared with a propensity score–matched historical cohort, supporting a potential therapeutic benefit of this cell-based intervention.
Impact: Provides comparative clinical effectiveness signals for a regenerative cell therapy in ARDS, an area with few disease-modifying treatments.
Clinical Implications: Invimestrocel may shorten ventilation duration and improve survival in pneumonia-induced ARDS; however, adoption requires confirmation in adequately powered randomized, blinded, placebo-controlled trials.
Key Findings
- Compared with matched historical controls (n=20), invimestrocel recipients (n=20) had higher ventilator-free days (14.8±11.0 vs 6.7±9.4; 95% CI 1.4–14.7; p=0.011).
- Survival was improved with invimestrocel (log-rank HR 0.330; 95% CI 0.116–0.938).
- Propensity score matching was applied to balance baseline characteristics between groups.
Methodological Strengths
- Use of propensity score matching to reduce confounding versus historical controls.
- Clinically meaningful endpoints (ventilator-free days, survival) reported with effect sizes and confidence intervals.
Limitations
- Small sample size (20 vs 20) and nonrandomized, historical comparison design.
- Potential residual confounding and selection bias despite matching; incomplete detailing of matching covariates in abstract.
Future Directions: Conduct randomized, blinded, placebo-controlled multicenter trials with predefined multiplicity control to confirm efficacy and safety and to identify responsive ARDS subphenotypes.
INTRODUCTION: Acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory lung injury often resulting from pneumonia. The efficacy and safety of invimestrocel in patients with pneumonia-induced ARDS have been demonstrated previously in a phase II randomized, open-label trial (the ONE-BRIDGE study). In this study, we aimed to compare data from the intervention (invimestrocel) arm of the ONE-BRIDGE study with matched historical data from a previously established cohort to provide further support for the beneficial effects of invimestrocel in patients with pneumonia-induced ARDS. METHODS: Twenty patients from the invimestrocel arm of the ONE-BRIDGE study (Invimestrocel group) and 104 from the historical cohort were included in this study. A matched historical data group (n = 20) was extracted from the historical cohort based on the propensity score analysis using age, sex, PaO RESULTS: Patients in the Invimestrocel group showed higher VFDs (14.8 ± 11.0 vs. 6.7 ± 9.4 days; 95 % confidence interval [CI], 1.4-14.7; p = 0.0110) and survival rates (log-rank testing; hazard ratio, 0.330; 95 % CI, 0.116-0.938) than those in the matched historical data group. CONCLUSIONS: The addition of invimestrocel to the standard treatment for pneumonia-induced ARDS may result in early withdrawal from the ventilator and lower mortality. However, further randomized, blinded, and placebo-controlled studies without or addressing multiplicity are required to confirm these findings.
3. Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure.
In 297 critically ill adults with acute respiratory failure, higher baseline GLP-1, but not GIP, correlated with systemic inflammatory markers and independently predicted 90-day mortality after adjustment for age, SOFA, and IL-6. GLP-1 may serve as a prognostic biomarker and enrich risk stratification, including in ARDS subgroups.
Impact: Links an endocrine pathway (GLP-1) to inflammation and mortality in acute respiratory failure, suggesting a readily measurable biomarker for prognostication and trial enrichment.
Clinical Implications: GLP-1 measurement at ICU admission could aid early risk stratification and selection for intensified monitoring or inclusion in precision trials; therapeutic implications of GLP-1 pathway modulation warrant investigation.
Key Findings
- GLP-1 levels were higher in nonsurvivors and in patients with or at risk for ARDS compared to those intubated for airway protection.
- GLP-1 correlated positively with systemic inflammatory biomarkers, but not with intestinal permeability markers.
- GLP-1 predicted 90-day mortality (adjusted OR 2.02 [1.23–3.31], p<0.01), whereas GIP showed no association with mortality or host response biomarkers.
Methodological Strengths
- Multivariable adjustment including age, SOFA score, and IL-6 with predefined primary analysis.
- Biomarker correlations across severity subgroups with baseline sampling at enrollment.
Limitations
- Retrospective single-system cohort with potential residual confounding and limited external generalizability.
- Single-timepoint measurements without serial trajectories or external validation.
Future Directions: Prospective multicenter validation with serial GLP-1 measurements, external replication, and mechanistic studies linking incretin signaling to critical illness inflammation; evaluate prognostic utility for ARDS trial enrichment.
OBJECTIVES: The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) have therapeutic effects in diabetes mellitus. Prior clinical studies suggest incretins are prognostic of adverse outcomes in critical illness. We investigated whether incretin levels indicate disease severity and clinical outcomes in patients with acute respiratory failure, a common cause of critical illness. DESIGN: Retrospective cohort study. SETTING: ICUs in UPMC Health Systems hospitals within Western Pennsylvania. PATIENTS: Two hundred ninety-seven critically ill adults with acute respiratory failure. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We measured GLP-1 and GIP levels in baseline samples collected at the time of study enrollment. We compared incretin levels across subgroups differing by severity of illness and investigated associations between incretins and markers of systemic host responses and intestinal permeability. In our primary analysis, we tested the association of each incretin level with 90-day mortality by logistic regression in unadjusted analyses and in analyses adjusted for age, Sequential Organ Failure Assessment score, and circulating interleukin-6 levels. GLP-1 levels were higher in nonsurvivors and patients with or at-risk for acute respiratory distress syndrome compared to those intubated for airway protection. GLP-1 levels also positively correlated with systemic immune response biomarkers but not with markers of intestinal permeability. GLP-1 levels positively correlated with mortality in unadjusted (odds ratio, 1.99 [1.55-2.56]; p < 0.01) and adjusted (2.02 [1.23-3.31]; p < 0.01) analyses. GIP levels were not associated with mortality or with host response biomarkers. CONCLUSIONS: GLP-1 but not GIP levels were positively associated with systemic inflammation and mortality in critically ill patients with acute respiratory failure. Increased circulating GLP-1 levels may serve as prognostic biomarkers to identify patients who are likely to have worse outcomes.